Johnson & Johnson vs iShares MBS ETF — how do they compare? Johnson & Johnson trades at $260.51 (market cap $626.09B), while iShares MBS ETF trades at $92.85. The key difference: Johnson & Johnson pays a 2.06% dividend while iShares MBS ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | MBB | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $96.91 |
52-Week Low | $172.78 | $92.72 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
MBB trades at $93.19 with minimal daily movement (+0.29%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.33-$0.34 per share. Institutional interest appears positive with Focus Financial Network increasing its stake by 13.8% according to recent SEC filings.
The mortgage-backed securities ETF faces headwinds from interest rate uncertainty while benefiting from institutional accumulation. Key risks include interest rate sensitivity and housing market volatility, balanced by steady income generation through dividends. Current technical weakness suggests cautious near-term positioning.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →